Published in J Am Dent Assoc on September 01, 2005
Addressing oral health disparities in diverse populations. J Am Dent Assoc (2005) 2.02
Characterizing traditionally defined periodontal disease in HIV+ adults. Community Dent Oral Epidemiol (2009) 0.97
Dental utilization among Hispanic adults in agricultural worker families in California's Central Valley. J Public Health Dent (2010) 0.90
Oral health associated with quality of life of people living with HIV/AIDS in Brazil. Health Qual Life Outcomes (2014) 0.82
A Community-based Oral Health Promotion Model for HIV Patients in Nairobi, East District in Kenya: a Study Protocol. J Public Health Res (2013) 0.81
Dental anxiety and the use of oral health services among people attending two HIV primary care clinics in Miami. Public Health Rep (2012) 0.81
The feasibility, acceptance, and key features of a prevention-focused oral health education program for HIV+ adults. AIDS Care (2013) 0.79
Utilization of dental care services among low-income HIV-positive persons receiving primary care in South Florida. AIDS Care (2011) 0.79
Patient perspectives on improving oral health-care practices among people living with HIV/AIDS. Public Health Rep (2012) 0.77
Retention of people living with HIV/AIDS in oral health care. Public Health Rep (2012) 0.77
HIV-related stigma in the dental setting: a qualitative study. Spec Care Dentist (2014) 0.76
Effects of a Brief Case Management Intervention Linking People With HIV to Oral Health Care: Project SMILE. Am J Public Health (2015) 0.75
Access to prevention. J Am Dent Assoc (2006) 0.75
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol (2003) 5.81
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf (2005) 3.05
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol (2013) 2.64
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis (2002) 2.29
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol (2004) 2.17
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS (2007) 2.10
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med (2002) 1.75
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS (2014) 1.66
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr (2007) 1.66
Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health (2004) 1.59
The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica (2006) 1.53
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. JPEN J Parenter Enteral Nutr (2002) 1.49
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS (2016) 1.45
Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.44
Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) (2009) 1.41
Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2002) 1.35
Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis (2009) 1.35
The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction (2005) 1.32
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol (2014) 1.32
Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2005) 1.31
CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis (2003) 1.29
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS (2009) 1.25
The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr (2006) 1.24
Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr (2008) 1.22
Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med (2002) 1.22
Contraceptive use among U.S. women with HIV. J Womens Health (Larchmt) (2007) 1.20
Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.18
Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS (2004) 1.18
A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis (2012) 1.17
Serum albumin is a powerful predictor of survival among HIV-1-infected women. J Acquir Immune Defic Syndr (2003) 1.16
Longitudinal trends in hazardous alcohol consumption among women with human immunodeficiency virus infection, 1995-2006. Am J Epidemiol (2009) 1.16
The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Prefer Adherence (2012) 1.15
Disclosure of complementary and alternative medicine use to health care providers among HIV-infected women. AIDS Patient Care STDS (2009) 1.14
Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse (2008) 1.14
The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis (2011) 1.13
Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med (2006) 1.13
Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS (2009) 1.12
Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS (2006) 1.11
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr (2009) 1.10
Neuropsychological functioning in a cohort of HIV infected women: importance of antiretroviral therapy. J Int Neuropsychol Soc (2002) 1.08
Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr (2012) 1.08
Predictors of reported influenza vaccination in HIV-infected women in the United States, 2006-2007 and 2007-2008 seasons. Prev Med (2010) 1.08
Mentoring early-career scientists for HIV research careers. Am J Public Health (2009) 1.08
Assessing the effect of HAART on change in quality of life among HIV-infected women. AIDS Res Ther (2006) 1.06
Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol (2005) 1.06
The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One (2013) 1.06
Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study. AIDS Behav (2008) 1.04
Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study. Antivir Ther (2010) 1.04
Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr (2012) 1.03
Experience of pain among women with advanced HIV disease. AIDS Patient Care STDS (2009) 1.02
Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril (2008) 0.99
The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. J Acquir Immune Defic Syndr (2011) 0.98
Association of child care burden and household composition with adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study. AIDS Patient Care STDS (2009) 0.98
Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr (2013) 0.97
Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am J Pathol (2002) 0.97
Perinatal depressive symptoms in HIV-infected versus HIV-uninfected women: a prospective study from preconception to postpartum. J Womens Health (Larchmt) (2011) 0.97
Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women. J Womens Health (Larchmt) (2006) 0.96
Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected women. J Acquir Immune Defic Syndr (2008) 0.96
Phenotype and functionality of CD4+ and CD8+ T cells in the upper reproductive tract of healthy premenopausal women. Am J Reprod Immunol (2013) 0.96
CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women. AIDS Educ Prev (2009) 0.95
Sexual serosorting among women with or at risk of HIV infection. AIDS Behav (2011) 0.95
High-throughput red blood cell antigen genotyping using a nanofluidic real-time polymerase chain reaction platform. Transfusion (2009) 0.95